Lebanon, NH: Celdara Medical, LLC announced today that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded a Phase II Small Business Innovation Research (SBIR) Fast-Track grant to fund company’s ongoing development of CM-CX1, a chimeric antigen receptor (CAR) T cell therapy for the treatment […]
Celdara Medical, LLC today announced that the National Institute of Aging’s Research and Entrepreneurial Development Immersion (REDI) initiative has awarded an R25 Entrepreneurship Enhancement Award to fund the company’s comprehensive training program focused on Alzheimer’s Disease: the Alzheimer’s-focused Celdara Medical High-Potential Entrepreneurs’ Fellowship (A-CHEF). This project builds on Celdara Medical’s […]
Position Description Celdara Medical, LLC (CM) is developing a portfolio of preclinical therapeutic assets, platforms, and companies. Each of these has a different development path, and we work with many different modalities, and in many different indications, but everything we do is singularly focused on saving lives and/or improving quality […]
Celdara Medical seeks outstanding scientists with interest in translational research and biotechnology for a paid Fellowship. Prior Fellows have jump-started careers in Venture Capital, Management Consulting, Technology Transfer, R&D, Medical Writing, and Business Development. An introductory virtual hour to answer questions about the program will be held on Thursday, August 25, 2022 at 12:00pm […]
Press Release Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) Phase I award to fund the company’s proof of concept studies on a new platform to improve chimeric antigen receptor (CAR) T cells […]
February 22, 2022 – Celdara Medical, LLC today announced that alumni of their DRIVEN Partnership Program have collectively surpassed $50M in follow-on funding. DRIVEN was established in 2018 as the Northeast’s NIH-funded Accelerator Hub. Led by Celdara Medical and Simbex, it has always had a singular goal: improve human health […]
January 26, 2022 – Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated […]